Literature DB >> 12185855

Can the cardiopulmonary 6-minute walk test reproduce the usual activities of patients with heart failure?

Guilherme Veiga Guimarães1, Giovanni Bellotti, Fernando Bacal, Amilcar Mocelin, Edimar Alcides Bocchi.   

Abstract

OBJECTIVE: The 6-minute walk test is an way of assessing exercise capacity and predicting survival in heart failure. The 6-minute walk test was suggested to be similar to that of daily activities. We investigated the effect of motivation during the 6-minute walk test in heart failure.
METHODS: We studied 12 males, age 45 +/- 12 years, ejection fraction 23 +/- 7%, and functional class III. Patients underwent the following tests: maximal cardiopulmonary exercise test on the treadmill (max), cardiopulmonary 6-minute walk test with the walking rhythm maintained between relatively easy and slightly tiring (levels 11 and 13 on the Borg scale) (6EB), and cardiopulmonary 6-minute walk test using the usual recommendations (6RU). The 6EB and 6RU tests were performed on a treadmill with zero inclination and control of the velocity by the patient.
RESULTS: The values obtained in the max, 6EB, and 6RU tests were, respectively, as follows: O2 consumption (ml.kg-1.min-1) 15.4 +/- 1.8, 9.8 +/- 1.9 (60 +/- 10%), and 13.3 +/- 2.2 (90 +/- 10%); heart rate (bpm) 142 +/- 12, 110 +/- 13 (77 +/- 9%), and 126 +/- 11 (89 +/- 7%); distance walked (m) 733 +/- 147, 332 +/- 66, and 470 +/- 48; and respiratory exchange ratio (R) 1.13 +/- 0.06, 0.9 +/- 0.06, and 1.06 +/- 0.12. Significant differences were observed in the values of the variables cited between the max and 6EB tests, the max and 6RU tests, and the 6EB and 6RU tests (p < 0.05).
CONCLUSION: Patients, who undergo the cardiopulmonary 6-minute walk test and are motivated to walk as much as they possibly can, usually walk almost to their maximum capacity, which may not correspond to that of their daily activities. The use of the Borg scale during the cardiopulmonary 6-minute walk test seems to better correspond to the metabolic demand of the usual activities in this group of patients.

Entities:  

Mesh:

Year:  2002        PMID: 12185855

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  6 in total

1.  Is the 6-min walking test a sub-maximal exercise test in heart failure patients?

Authors:  Vitor Oliveira Carvalho; Guilherme Veiga Guimarães
Journal:  Eur J Appl Physiol       Date:  2009-08-27       Impact factor: 3.078

2.  Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial.

Authors:  Gilberto M Sperandio da Silva; Mayara C Chambela; Andrea S Sousa; Luiz Henrique C Sangenis; Sergio S Xavier; Andréa R Costa; Pedro Emmanuel A A Brasil; Alejandro M Hasslocher-Moreno; Roberto M Saraiva
Journal:  Trials       Date:  2012-12-27       Impact factor: 2.279

3.  Effects of resistance training in older women with knee osteoarthritis and total knee arthroplasty.

Authors:  Emmanuel Gomes Ciolac; José Messias Rodrigues da Silva; Júlia Maria D'Andréa Greve
Journal:  Clinics (Sao Paulo)       Date:  2015-01       Impact factor: 2.365

4.  Reproducibility of the self-controlled six-minute walking test in heart failure patients.

Authors:  Guilherme Veiga Guimarães; Vitor Oliveira Carvalho; Edimar Alcides Bocchi
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

5.  Alternatives to Aerobic Exercise Prescription in Patients with Chronic Heart Failure.

Authors:  Mayron F Oliveira; Gabriela Zanussi; Bianca Sprovieri; Denise M L Lobo; Luiz E Mastrocolla; Iracema I K Umeda; Priscila A Sperandio
Journal:  Arq Bras Cardiol       Date:  2016-01-22       Impact factor: 2.000

6.  Concurrent Training Increases Serum Brain-Derived Neurotrophic Factor in Older Adults Regardless of the Exercise Frequency.

Authors:  Ermilo Canton-Martínez; Iván Rentería; Patricia C García-Suárez; José Moncada-Jiménez; Juan Pablo Machado-Parra; Fabio Santos Lira; David K Johnson; Alberto Jiménez-Maldonado
Journal:  Front Aging Neurosci       Date:  2022-03-07       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.